Aligos Therapeutics Inc
NASDAQ:ALGS
Income Statement
Earnings Waterfall
Aligos Therapeutics Inc
Income Statement
Aligos Therapeutics Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Revenue |
0
N/A
|
1
N/A
|
2
+170%
|
4
+63%
|
4
+9%
|
6
+38%
|
8
+35%
|
11
+31%
|
14
+30%
|
14
+1%
|
17
+23%
|
16
-5%
|
16
-5%
|
14
-11%
|
8
-42%
|
6
-25%
|
4
-34%
|
3
-17%
|
3
-3%
|
3
-17%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(98)
|
(106)
|
(116)
|
(129)
|
(133)
|
(142)
|
(135)
|
(124)
|
(111)
|
(97)
|
(95)
|
(95)
|
(98)
|
(100)
|
(101)
|
(101)
|
(89)
|
(90)
|
(82)
|
(89)
|
|
| Selling, General & Administrative |
(18)
|
(20)
|
(23)
|
(25)
|
(29)
|
(29)
|
(30)
|
(29)
|
(26)
|
(25)
|
(24)
|
(25)
|
(25)
|
(26)
|
(26)
|
(24)
|
(19)
|
(17)
|
(16)
|
(17)
|
|
| Research & Development |
(80)
|
(85)
|
(92)
|
(104)
|
(104)
|
(113)
|
(105)
|
(95)
|
(85)
|
(72)
|
(72)
|
(70)
|
(73)
|
(71)
|
(76)
|
(76)
|
(70)
|
(68)
|
(61)
|
(68)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
(4)
|
(4)
|
(4)
|
|
| Operating Income |
(98)
N/A
|
(105)
-7%
|
(113)
-8%
|
(125)
-10%
|
(128)
-3%
|
(136)
-6%
|
(127)
+7%
|
(113)
+11%
|
(98)
+14%
|
(82)
+16%
|
(78)
+5%
|
(78)
0%
|
(82)
-5%
|
(86)
-5%
|
(94)
-8%
|
(95)
-1%
|
(85)
+10%
|
(86)
-2%
|
(79)
+9%
|
(87)
-10%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
1
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
3
|
3
|
4
|
4
|
3
|
3
|
2
|
2
|
2
|
2
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(4)
|
(7)
|
(7)
|
(6)
|
0
|
0
|
0
|
(4)
|
0
|
0
|
0
|
|
| Total Other Income |
(12)
|
(12)
|
(12)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
1
|
(3)
|
(17)
|
15
|
15
|
(43)
|
32
|
3
|
(1)
|
|
| Pre-Tax Income |
(108)
N/A
|
(116)
-7%
|
(125)
-8%
|
(125)
+0%
|
(128)
-3%
|
(136)
-6%
|
(126)
+7%
|
(112)
+11%
|
(96)
+14%
|
(83)
+13%
|
(81)
+2%
|
(81)
+1%
|
(87)
-8%
|
(99)
-14%
|
(76)
+24%
|
(77)
-2%
|
(131)
-71%
|
(53)
+60%
|
(74)
-40%
|
(86)
-17%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(109)
|
(116)
|
(125)
|
(125)
|
(128)
|
(136)
|
(126)
|
(112)
|
(96)
|
(83)
|
(82)
|
(82)
|
(88)
|
(100)
|
(76)
|
(77)
|
(131)
|
(53)
|
(74)
|
(86)
|
|
| Net Income (Common) |
(109)
N/A
|
(116)
-7%
|
(125)
-8%
|
(125)
+0%
|
(128)
-3%
|
(136)
-6%
|
(126)
+7%
|
(112)
+11%
|
(96)
+14%
|
(83)
+13%
|
(82)
+1%
|
(82)
+1%
|
(88)
-7%
|
(100)
-14%
|
(76)
+24%
|
(77)
-2%
|
(131)
-71%
|
(53)
+59%
|
(74)
-39%
|
(86)
-17%
|
|
| EPS (Diluted) |
-2.97
N/A
|
-3.1
-4%
|
-3.31
-7%
|
-2.94
+11%
|
-3.22
-10%
|
-3.2
+1%
|
-2.96
+8%
|
-2.61
+12%
|
-2.25
+14%
|
-1.95
+13%
|
-1.91
+2%
|
-1.88
+2%
|
-34.11
-1 714%
|
-15.94
+53%
|
-12.08
+24%
|
-12.26
-1%
|
-20.94
-71%
|
-6.11
+71%
|
-7.16
-17%
|
-8.33
-16%
|
|